Cure Ventures
Cure Ventures is a Boston-based venture capital firm established in 2020, specializing in investments in the life sciences and medical technologies sectors. The firm focuses on seed-stage investments in biotechnology, pharmaceuticals, medical devices, and medtech companies that demonstrate exceptional growth potential and are dedicated to addressing unmet medical needs. By discovering and enabling innovative firms, Cure Ventures aims to accelerate the development and market introduction of novel cures, ultimately benefiting global patient populations. As a Registered Investment Adviser, the firm prioritizes strategic partnerships that align with its mission to enhance healthcare outcomes through cutting-edge solutions.
Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications.
Clasp Therapeutics
Series A in 2024
Clasp Therapeutics is focused on advancing cancer treatment through its innovative immunotherapeutics platform. The company develops precision medicines designed to enhance the immune system's ability to identify and eliminate challenging tumors that possess common driver mutations, irrespective of the tumor type. By enabling the targeting of cancer-specific markers, Clasp Therapeutics aims to allow for precise and selective destruction of tumor cells, thereby improving therapeutic outcomes in the field of immuno-oncology.
Kenai Therapeutics
Series A in 2024
Kenai Therapeutics is a biotechnology company dedicated to developing therapies for neurodegenerative movement disorders. The company specializes in off-the-shelf neuron replacement therapies, which serve as effective disease-modifying treatments for various neurological conditions. By providing innovative therapeutic options, Kenai Therapeutics aims to equip healthcare professionals with advanced methods for treating disorders such as Parkinson's disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.